JP2018508516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508516A5 JP2018508516A5 JP2017546075A JP2017546075A JP2018508516A5 JP 2018508516 A5 JP2018508516 A5 JP 2018508516A5 JP 2017546075 A JP2017546075 A JP 2017546075A JP 2017546075 A JP2017546075 A JP 2017546075A JP 2018508516 A5 JP2018508516 A5 JP 2018508516A5
- Authority
- JP
- Japan
- Prior art keywords
- eribulin
- breast cancer
- medicament
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 27
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 claims 19
- 206010006187 Breast cancer Diseases 0.000 claims 15
- 208000026310 Breast neoplasm Diseases 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 229960003649 eribulin Drugs 0.000 claims 14
- 229960002621 pembrolizumab Drugs 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 229940124060 PD-1 antagonist Drugs 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 4
- 229960000439 eribulin mesylate Drugs 0.000 claims 4
- 230000002055 immunohistochemical effect Effects 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000003183 carcinogenic agent Substances 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128373P | 2015-03-04 | 2015-03-04 | |
| US62/128,373 | 2015-03-04 | ||
| US201562264068P | 2015-12-07 | 2015-12-07 | |
| US62/264,068 | 2015-12-07 | ||
| PCT/US2016/020734 WO2016141209A1 (en) | 2015-03-04 | 2016-03-03 | Combination of a pd-1 antagonist and eribulin for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508516A JP2018508516A (ja) | 2018-03-29 |
| JP2018508516A5 true JP2018508516A5 (enExample) | 2019-04-18 |
| JP6951248B2 JP6951248B2 (ja) | 2021-10-20 |
Family
ID=55586425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546075A Active JP6951248B2 (ja) | 2015-03-04 | 2016-03-03 | がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10945990B2 (enExample) |
| EP (1) | EP3265122B1 (enExample) |
| JP (1) | JP6951248B2 (enExample) |
| KR (1) | KR20170122810A (enExample) |
| CN (1) | CN107810013B (enExample) |
| AU (1) | AU2016226157B2 (enExample) |
| BR (1) | BR112017018872A2 (enExample) |
| CA (1) | CA2978311A1 (enExample) |
| IL (1) | IL254133B (enExample) |
| MX (1) | MX386547B (enExample) |
| RU (1) | RU2737216C2 (enExample) |
| SG (1) | SG11201706872SA (enExample) |
| WO (1) | WO2016141209A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005250487B2 (en) | 2004-06-03 | 2012-03-29 | Eisai R&D Management Co., Ltd | Intermediates for the preparation of analogs of halichondrin B |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| AU2010232347A1 (en) | 2009-03-30 | 2011-09-29 | Eisai R&D Management Co., Ltd. | Liposome composition |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| KR20170122810A (ko) | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| AU2016275574B2 (en) * | 2015-06-11 | 2019-07-11 | Bionomics Limited | Pharmaceutical combination and uses thereof |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| EP3449921B1 (en) | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| MX2019003994A (es) * | 2016-10-14 | 2019-09-19 | Merck Sharp & Dohme | Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial. |
| EP3528834A4 (en) * | 2016-10-21 | 2020-07-01 | Merck Sharp&Dohme Corp. | TREATMENT OF CANCER USING A COMBINATION OF A PD-1 ANTAGONIST AND AN IL-27 ANTAGONIST |
| WO2019017497A1 (en) * | 2017-07-21 | 2019-01-24 | Eisai R&D Management Co., Ltd. | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US20190380998A1 (en) | 2018-06-15 | 2019-12-19 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| WO2019240871A1 (en) * | 2018-06-15 | 2019-12-19 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing breast cancer with s-equol |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| KR20220114532A (ko) * | 2019-10-28 | 2022-08-17 | 주식회사 엔지켐생명과학 | 암의 치료를 위한 방법 및 조성물 |
| WO2025049528A1 (en) * | 2023-08-29 | 2025-03-06 | Cullinan Amber Corp. | Combination therapies for cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| CA2755266C (en) | 1998-06-17 | 2014-08-12 | Eisai R&D Management Co., Ltd. | Intermediates for preparing macrocyclic analogs |
| ATE477273T1 (de) | 1998-12-01 | 2010-08-15 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| WO2004004771A1 (ja) | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
| MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
| EP2270051B1 (en) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
| AU2005250487B2 (en) | 2004-06-03 | 2012-03-29 | Eisai R&D Management Co., Ltd | Intermediates for the preparation of analogs of halichondrin B |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| EP2200992B1 (en) | 2007-10-03 | 2014-02-26 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin b analogs |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| JP2012510429A (ja) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよびその使用方法 |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| KR20250091300A (ko) | 2008-12-09 | 2025-06-20 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| BR112012018232B8 (pt) | 2010-01-26 | 2023-01-10 | Eisai R&D Man Co Ltd | Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina |
| EP2680839A1 (en) | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| SG193489A1 (en) * | 2011-03-18 | 2013-10-30 | Eisai R&D Man Co Ltd | Methods and compositions for predicting response to eribulin |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| CA2892780A1 (en) * | 2012-12-04 | 2014-06-12 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014159562A1 (en) | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| JP2016520662A (ja) | 2013-06-11 | 2016-07-14 | ノバルティス アーゲー | Ｐｉ３ｋ阻害剤および微小管不安定化剤の医薬組み合わせ |
| AU2014299699B2 (en) * | 2013-06-26 | 2019-10-10 | Eisai R&D Management Co., Ltd. | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| KR20240144452A (ko) | 2014-03-05 | 2024-10-02 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료 |
| EP3148526B1 (en) | 2014-05-28 | 2021-01-06 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
| KR20170122810A (ko) | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합 |
-
2016
- 2016-03-03 KR KR1020177027617A patent/KR20170122810A/ko not_active Ceased
- 2016-03-03 JP JP2017546075A patent/JP6951248B2/ja active Active
- 2016-03-03 WO PCT/US2016/020734 patent/WO2016141209A1/en not_active Ceased
- 2016-03-03 AU AU2016226157A patent/AU2016226157B2/en not_active Ceased
- 2016-03-03 US US15/554,540 patent/US10945990B2/en active Active
- 2016-03-03 EP EP16710891.9A patent/EP3265122B1/en not_active Revoked
- 2016-03-03 CN CN201680025588.3A patent/CN107810013B/zh not_active Expired - Fee Related
- 2016-03-03 RU RU2017132877A patent/RU2737216C2/ru active
- 2016-03-03 BR BR112017018872A patent/BR112017018872A2/pt not_active IP Right Cessation
- 2016-03-03 MX MX2017011206A patent/MX386547B/es unknown
- 2016-03-03 CA CA2978311A patent/CA2978311A1/en not_active Abandoned
- 2016-03-03 SG SG11201706872SA patent/SG11201706872SA/en unknown
-
2017
- 2017-08-24 IL IL254133A patent/IL254133B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508516A5 (enExample) | ||
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2018512391A5 (enExample) | ||
| JP7578643B2 (ja) | 異常な細胞成長を処置するための方法および組成物 | |
| US20230103007A1 (en) | Combination therapy for treating abnormal cell growth | |
| JP2019530706A5 (enExample) | ||
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2022022392A (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| JP2016530280A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| CN110536702A (zh) | 使用hsp90抑制剂治疗癌症的方法 | |
| JP2015517523A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| RU2020122083A (ru) | Способ снижения ототоксичности у педиатрических пациентов, получающих химиотерапию препаратами платины | |
| JPWO2019241442A5 (enExample) | ||
| JP2021505669A5 (enExample) | ||
| AU2023336057A1 (en) | Dosage regimens of estrogen receptor degraders | |
| ES3036485T3 (en) | Combination comprising everolimus and amcenestrant | |
| JP2019501957A5 (enExample) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| US20200054634A1 (en) | Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer | |
| JP2018522881A5 (enExample) | ||
| TWI707681B (zh) | 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途 | |
| US20220409582A1 (en) | Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma |